Patents by Inventor Donald P. Matthews

Donald P. Matthews has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5684004
    Abstract: The present invention relates to novel triaryl-ethylene derivatives that are useful as anti-neoplastic agents, antiatherosclerotic agents, and hypocholesterolemic agents.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: November 4, 1997
    Assignee: Merrell Pharmaceuticals, Inc.
    Inventors: Donald A. Kaplan, Donald P. Matthews, Alan J. Bitonti, William A. Van Sickle
  • Patent number: 5616702
    Abstract: This invention relates to certain novel 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives, and compositions thereof, which are useful in the treatment of patients afflicted with neoplastic or viral disease states.
    Type: Grant
    Filed: December 22, 1994
    Date of Patent: April 1, 1997
    Assignee: Merrell Pharmaceuticals Inc.
    Inventors: Michael L. Edwards, Donald P. Matthews, James R. McCarthy
  • Patent number: 5607925
    Abstract: This invention relates to certain novel 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives, and compositions thereof, which are useful in the treatment of patients afflicted with neoplastic or viral disease states.
    Type: Grant
    Filed: November 1, 1994
    Date of Patent: March 4, 1997
    Assignee: Merrell Pharmaceuticals Inc.
    Inventors: Donald P. Matthews, Alan J. Bitonti, Michael L. Edwards, James R. McCarthy
  • Patent number: 5589587
    Abstract: The present invention is directed toward a novel process of preparing 2'-exocyclic vinylfluoride derivatives of cytidine analogues for use as ribonucleotide reductase inhibitors. The novel process of the present invention utilizes a cytidine derivative as the required starting material and provides the ribonucleotide reductase inhibitor in a more efficient than the reaction sequence. The process is more efficient than the process disclosed by McCarthy et al. in European Patent Application Publication No. 0 372 268 published Jun. 13, 1990, in that it requires fewer chromatographies and results in an overall yield of greater than 25% for the five steps. The present invention further provides the ribonucleotide reductase inhibitor in a four step reaction sequence and results in an overall yield of greater than 35%.
    Type: Grant
    Filed: April 10, 1995
    Date of Patent: December 31, 1996
    Assignee: Merrell Pharmaceuticals Inc.
    Inventors: James R. McCarthy, Donald P. Matthews, Jeffrey S. Sabol, James R. McConnell, Richard E. Donaldson, Robert Duquid
  • Patent number: 5525633
    Abstract: The present invention relates to novel triaryl-ethylene derivatives that are useful as anti-neoplastic agents, antiatherosclerotic agents, and hypocholesterolemic agents.
    Type: Grant
    Filed: June 15, 1994
    Date of Patent: June 11, 1996
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Donald P. Matthews, Alan J. Bitonti, William A. Van Sickle, Donald A. Kaplan
  • Patent number: 5512678
    Abstract: The present invention provides novel 5-(1-fluorovinyl)-1H-pyrimidine-2,4-dione derivatives which are useful as antineoplastic agents by themselves or in conjunctive therapy with the antineoplastic agent 5-fluorouracil.
    Type: Grant
    Filed: April 29, 1994
    Date of Patent: April 30, 1996
    Assignee: Merrell Pharmaceuticals Inc.
    Inventors: James R. McCarthy, Donald P. Matthews, Jeffrey S. Sabol
  • Patent number: 5508393
    Abstract: The present invention is directed toward a novel process of preparing 2'-exocyclic vinylfluoride derivatives of cytidine analogues for use as ribonucleotide reductase inhibitors. The novel process of the present invention utilizes a cytidine derivative as the required starting material and provides the ribonucleotide reductase inhibitor in a more efficient five step reaction sequence. The present invention further provides the ribonucleotide reductase inhibitor in a four step reaction sequence and results in an overall yield of greater than 35%.
    Type: Grant
    Filed: May 11, 1995
    Date of Patent: April 16, 1996
    Assignee: Hoeschst Marion Roussel, Inc.
    Inventors: James R. McCarthy, Donald P. Matthews, Jeffrey S. Sabol, James R. McConnell, Richard E. Donaldson, Robert Duquid
  • Patent number: 5378693
    Abstract: This invention relates to certain novel 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives, and compositions thereof, which are useful in the treatment of patients afflicted with neoplastic or viral disease states.
    Type: Grant
    Filed: August 27, 1993
    Date of Patent: January 3, 1995
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: James R. McCarthy, Michael L. Edwards, Donald P. Matthews
  • Patent number: 5189052
    Abstract: Imidazole-2-thione derivatives useful as antihypertensive agents are described herein. The compounds are obtained by cyclization of an appropriate open-chain compound such as an appropriately substituted thiourea.
    Type: Grant
    Filed: December 20, 1989
    Date of Patent: February 23, 1993
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Donald P. Matthews, James R. McCarthy, Jeffrey P. Whitten, Robert J. Broersma, Jr.
  • Patent number: 5147863
    Abstract: This invention relates to novel derivatives of 2,2'-bi-1H-imidazoles, to the processes and intermediates used in their preparation, to their ability to exert the pharmacologic effects of lowering high blood pressure and of increasing heart contractile force and to their use as chemotherpauetic agents useful in treating cardiac insufficiency and hypertension.
    Type: Grant
    Filed: October 17, 1990
    Date of Patent: September 15, 1992
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Donald P. Matthews, Jeffrey P. Whitten, James R. McCarthy
  • Patent number: 5120764
    Abstract: This invention relates to certain inhibitors of lysyl oxidase and their use in the treatment of diseases and conditions associated with the abnormal deposition of collagen.
    Type: Grant
    Filed: November 1, 1988
    Date of Patent: June 9, 1992
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: James R. McCarthy, Charlotte L. Barney, Donald P. Matthews, Philippe Bey
  • Patent number: 5112852
    Abstract: The present invention relates to allenyl amines, more specifically, .beta.-ethenylidene(substituted) ethanamines, possessing antihypertensive activity, and having the general formula ##STR1## wherein n is the integer 0, 1 or 2; each X independently is a substituent selected from the group consisting of loweralkyl, halo, --O--(loweralkyl), --S--(loweralkyl), --SO--(loweralkyl), --SO.sub.2 --(loweralkyl), CO.sub.2 R and CH.sub.2 OR, wherein R is loweralkyl and each loweralkyl group is from 1 to about 6 carbon atoms, or the pharmaceutically-acceptable addition salts thereof. These compounds are prepared by a novel reaction of a protected N,N-bis(trimethylsilyl)-4-methoxy-2-butynylamine compound with a metallo-organic compound, with subsequent removal of the silyl protecting groups to provide the desired compound.
    Type: Grant
    Filed: April 21, 1989
    Date of Patent: May 12, 1992
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: James R. McCarthy, Thomas M. Bargar, Charlotte L. Barney, Donald P. Matthews, Robert J. Broersma
  • Patent number: 5068465
    Abstract: This invention relates to novel 3-aryl-2-fluoro-1-olefins and their pharmacological use as dopamine beta-hydroxylase DBH inhibitors in the treatment of DBH mediated conditions such as hypertension.
    Type: Grant
    Filed: June 15, 1990
    Date of Patent: November 26, 1991
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: James R. McCarthy, Charlotte L. Barney, Donald P. Matthews
  • Patent number: 5057613
    Abstract: Imidazole-2-thione derivatives useful as antihypertensive agents are described herein. The compounds are obtained by cyclization of an appropriate open-chain compound such as an appropriately substituted thiourea.
    Type: Grant
    Filed: October 27, 1987
    Date of Patent: October 15, 1991
    Assignee: Merrell Dow Pharmaceuticals
    Inventors: Donald P. Matthews, James R. McCarthy, Jeffrey P. Whitten, Robert J. Broersma, Jr.
  • Patent number: 5017591
    Abstract: This invention relates to novel (aryl or heteroaromatic methyl)-2,2'-1H-biimidazoles; to a process for their production comprising of reacting an appropriate alpha-brominated or alpha-chlorinated, substituted or nonsubstituted, methylated monoaromatic ring compound with 2,2'-bi-1H-imidazole in a solvent such as ethanol in the presence of a base such as sodium hydroxide under reflux conditions; and to pharmaceutical compositions and methods of treating hypertension with such compounds.
    Type: Grant
    Filed: March 2, 1990
    Date of Patent: May 21, 1991
    Assignee: Merrell Dow Pharmaceuticals
    Inventors: Donald P. Matthews, Jeffrey P. Whitten, James B. McCarthy
  • Patent number: 4981868
    Abstract: This invention relates to novel 3-heteroaryl-2-fluoro-1-olefins and their pharmacological use as dopamine beta-hydroxylase DBH inhibitors in the treatment of DBH mediated conditions such as hypertension.
    Type: Grant
    Filed: July 25, 1989
    Date of Patent: January 1, 1991
    Assignee: Merrell Dow Pharmaceutical
    Inventors: James R. McCarthy, Donald P. Matthews, Charlotte L. Barney
  • Patent number: 4929744
    Abstract: This invention relates to a process for preparing (aryl) or heteroaromatic methyl)-2,2'-1H-biimidazoles. Reacting an appropriate alpha-brominated or alpha-chlorinated, substituted or non-substituted, methylated monoaromatic ring compound with 2,2'-bi-1H-imidazole in a solvent such as ethanol in the presence of a base such as sodium hydroxide under reflux conditions; and to pharmaceutical compositions and methods of treating hypertension with such compounds.
    Type: Grant
    Filed: March 27, 1989
    Date of Patent: May 29, 1990
    Assignee: Merrell Dow Pharmaceuticals
    Inventors: Donald P. Matthews, James R. McCarthy, Jeffrey P. Whitten
  • Patent number: 4857663
    Abstract: N-(3-Dialkylamino-2-propenylidene)-N-alkylalkanaminium salts substituted in the 2-position with an ether or thioether and having the formula ##STR1## are active as hypoglycemic agents.
    Type: Grant
    Filed: November 16, 1988
    Date of Patent: August 15, 1989
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Eugene R. Wagner, Donald P. Matthews, Charlotte L. Barney
  • Patent number: 4847288
    Abstract: The present invention relates to compounds which are allenyl amines, more specifically, .beta.-ethenylidene-(substituted)ethanamines, possessing antihypertensive activity. They are prepared by a noval reaction of a protected N,N-bis(trimethylsilyl)-4-methoxy-2-butynylamine compound with a metallo-organic compound, with subsequent removal of the silyl protecting groups to provide the desired compound.
    Type: Grant
    Filed: February 8, 1988
    Date of Patent: July 11, 1989
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: James R. McCarthy, Thomas M. Bargar, Charlotte L. Barney, Donald P. Matthews, Robert J. Broersma
  • Patent number: 4839375
    Abstract: This invention relates to novel (aryl or heteroaromatic methyl)-2,2'-1H-biimidazoles; to a process for their production comprising of reacting an appropriate alpha-brominated or alpha-chlorinated, substituted or non-substituted, methylated monoaromatic ring compound with 2,2'-bi-1H-imidazole in a solvent such as ethanol in the presence of a base such as sodium hydroxide under reflux conditions; and to pharmaceutical compositions and methods of treating hypertension with such compounds.
    Type: Grant
    Filed: July 28, 1987
    Date of Patent: June 13, 1989
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Donald P. Matthews, Jeffrey P. Whitten, James R. McCarthy